Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Hypopigmented macule, Hyperkeratotic papule, Punctate palmoplantar hyperkeratosis, and Palmoplantar keratoderma; and common findings: Ectopic calcification. 15 total HPO annotations.
Data assembled from 7 of 12 sources · Last updated Sep 18, 2026, 3:08 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 5 | Abnormal nail morphology, Hyperkeratotic papule, Punctate palmoplantar hyperkeratosis |
ENPP1 encodes ectonucleotide pyrophosphatase/phosphodiesterase 1 (925 aa). Nucleotide pyrophosphatase that generates diphosphate (PPi) and functions in bone mineralization and soft tissue calcification by regulating pyrophosphate levels. Highest expression in Uterus (42.3 TPM) and Thyroid (26.5 TPM).
Hypopigmentation-punctate palmoplantar keratoderma syndrome has limited evidence linking it to mutations in the ENPP1 gene on chromosome 6.
ENPP1 is classified as a druggable target (Cell Surface, Druggable Genome, and Enzyme categories) with score 0.0.
Genetic testing for ENPP1 is available. Testing is considered research-grade for diagnosis.
Phenotype severity distribution: 4 always present features, 1 common feature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for hypopigmentation-punctate palmoplantar keratoderma syndrome.
73 publications have been identified in PubMed for hypopigmentation-punctate palmoplantar keratoderma syndrome. Research spans Case Report / Case Series (47%), Review / Meta-Analysis (32%), and Basic Science / Preclinical (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 34 | 47% |
Research summaries | 23 | 32% |
Laboratory research | 8 | 11% |
Disease patterns and progression | 3 | 4% |
New treatment approaches | 3 | 4% |
Other research | 1 | 1% |
Clinical study results | 1 | 1% |
Chen B (2026). [PMID: 41889596](https://pubmed.ncbi.nlm.nih.gov/41889596/). *Int Med Case Rep J*. [Case Report / Case Series]
Cadiravane S (2026). [PMID: 41818120](https://pubmed.ncbi.nlm.nih.gov/41818120/). *J Assoc Physicians India*. [Case Report / Case Series]
Nykaza I (2026). [PMID: 41621675](https://pubmed.ncbi.nlm.nih.gov/41621675/). *J Am Acad Dermatol*. [Review / Meta-Analysis]
Rossel VSVJ (2026). [PMID: 41781296](https://pubmed.ncbi.nlm.nih.gov/41781296/). *J Dermatol Sci*. [Basic Science / Preclinical]
Protonotarios I (2026). [PMID: 41936932](https://pubmed.ncbi.nlm.nih.gov/41936932/). *Hellenic J Cardiol*. [Review / Meta-Analysis]
Alibrahim L (2026). [PMID: 41755622](https://pubmed.ncbi.nlm.nih.gov/41755622/). *Dermatol Reports*. [Gene Therapy / Novel Therapeutics]
Nykaza I (2026). [PMID: 41621676](https://pubmed.ncbi.nlm.nih.gov/41621676/). *J Am Acad Dermatol*. [Review / Meta-Analysis]
Assas M (2026). [PMID: 41914522](https://pubmed.ncbi.nlm.nih.gov/41914522/). *Spec Care Dentist*. [Review / Meta-Analysis]
Piątkiewicz M (2026). [PMID: 41884385](https://pubmed.ncbi.nlm.nih.gov/41884385/). *Clin Cosmet Investig Dermatol*. [Review / Meta-Analysis]
Almousa A (2026). [PMID: 41502835](https://pubmed.ncbi.nlm.nih.gov/41502835/). *Cureus*. [Case Report / Case Series]